negotiated the 1987 treaty believes that there is no basis for a reevaluation. "It was agreed that the [NCI] test kit was based on information gleaned from LAV [the Institut Pasteur version of the virus]", says Robert Charrow, a lawyer who was then in the HHS general counsel's office. Because the signatories had already acknowledged that Gallo's work had incorporated Montagnier's virus, "By definition [the treaty] could not be renegotiated. " He believes the Fischinger memorandum (which he has seen) adds nothing new.
Michael Astrue , HHS general counsel, says he is familiar with the allegations, but he would not comment on the possibility of renegotiating the treaty.
The congressional oversight and investigations subcommittee under Representative John Dingell (Democrat, Michigan) , which has taken an active interest in the matter, has so far made no moves in reaction to the latest disclosures. With an NIH inquiry in progress (see Nature 343, 680, 22 February 1990) , Dingell is expected to wait for a report from the investigators before taking new action .
In response to a January Jetter from Dingell, NIH director William Raub outlined 14 specific allegations the agency's Office of Scientific Integrity was investigating. Raub said that attention would be focused on "questions about how many isolates [came] from AIDS patients and when this occurred" in Gallo's laboratory, and "questions about the H-9 cell line used" in the laboratory.
Although Crewdson's account has earned surprising little press attention in the United States, the French press has been riveted. Montagnier has been quoted in Le Monde as appealing to Gallo to "at last accept the evidence" and admit the true source of the AIDS virus . Such statements may threaten the treaty as much as the Crewdson allegations.
Attached to the 1987 document is a 'scientific history' of the discovery of the AIDS virus (Nature 326, 435 ; 1987) . And in the text of the treaty is a clause stating that Robert Gallo and Luc Montagnier agree not to "make nor publish any statement which would or could be construed as contradicting or compromising the integrity of the said scientific history". Pasteur lawyer Millstein says he "did not advise Montagnier to make those statements" . Nevertheless , the contrary reactions from opposite sides of the Atlantic suggests that the debate may well intensify. As the NIH , with the help of a new 11-person committee selected by the National Academy of Science, continues its secret inquiry, one observer wryly notes "in Paris, they' re rioting in the I The vote was unanimous, although neither Gabriel Schmergel, chief executive officer of Genetics Institute, or Fildes of Cetus, were present because of prior commitments. Both companies support changes to the act and are opposed to the proposed patent legislation. In a joint statement, they said that the act stands to "perpetuate or create market monopolies for highly profitable products such as recombinant human growth hormone and erythropoietin", two products with orphan drug status. Katharine Russell of Cetus says "to see the trade association take an anti-competitive position" on these matters is "lamentable".
The Orphan Drug Act was designed to provide tax incentives and a seven-year marketing monopoly in the United States to companies developing drugs for rare diseases affecting fewer than 200,000 patients.
Also at issue is the 'Boucher bill', introduced last month by Representative Rick Boucher (Democrat, Virginia). The bill would provide the International Trade Commission with the authority to exclude foreign products made using a host cell, DNA sequence, or vector patented in the United States, closing what the bill's sponsors believe to be an unfair legal loophole.
Genetics Institute would be affected by the legislation, as it would prevent the importation into the United States of its EPO product, which is produced in Japan by its licensee, Chugai Pharmaceuticals.
Godown was both "surprised and saddened" by the news and says that "this dispute arises out of a difference of opinion concerning what is best for the long-term interests of the development of the biotechnology industry".
Diane Gershon
